Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 1
2001 2
2002 2
2003 3
2004 3
2005 1
2006 2
2007 2
2008 1
2009 4
2010 4
2011 6
2012 7
2013 8
2014 5
2015 3
2016 6
2017 4
2018 16
2019 16
2020 10
2021 3
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33293266

99 results
Results by year
Filters applied: . Clear all
Page 1
A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.
Johnson SC, Williams DC, Brinton D, Chew M, Simpson A, Andrews AL. Johnson SC, et al. Hosp Pediatr. 2021 Jan;11(1):88-93. doi: 10.1542/hpeds.2020-0188. Epub 2020 Dec 8. Hosp Pediatr. 2021. PMID: 33293266
Demographic and treatment variability of refractory kawasaki disease: a multicenter analysis from 2005 to 2009.
Ghelani SJ, Pastor W, Parikh K. Ghelani SJ, et al. Hosp Pediatr. 2012 Apr 1;2(2):71-6. doi: 10.1542/hpeds.2011-00112. Hosp Pediatr. 2012. PMID: 24510952 Free article.
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC; KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. Roberts SC, et al. Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3. Contemp Clin Trials. 2019. PMID: 30840903 Clinical Trial.
Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL, Zhao SL. Han CL, et al. Med Sci Monit. 2018 Oct 11;24:7264-7270. doi: 10.12659/MSM.908678. Med Sci Monit. 2018. PMID: 30307902 Free PMC article. Clinical Trial.
Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q. Chan H, et al. BMC Pediatr. 2019 May 17;19(1):158. doi: 10.1186/s12887-019-1504-9. BMC Pediatr. 2019. PMID: 31101091 Free PMC article. Review.
Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB, Mitchell C, Beukelman T. Crayne CB, et al. Pediatr Rheumatol Online J. 2019 Nov 27;17(1):77. doi: 10.1186/s12969-019-0380-z. Pediatr Rheumatol Online J. 2019. PMID: 31775898 Free PMC article.
Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S. Mori M, et al. J Rheumatol. 2012 Apr;39(4):864-7. doi: 10.3899/jrheum.110877. Epub 2012 Feb 15. J Rheumatol. 2012. PMID: 22337241 Clinical Trial.
Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR. Jone PN, et al. Pediatr Infect Dis J. 2018 Oct;37(10):976-980. doi: 10.1097/INF.0000000000001951. Pediatr Infect Dis J. 2018. PMID: 29461447 Free PMC article.
Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O. Burns JC, et al. J Pediatr. 2008 Dec;153(6):833-8. doi: 10.1016/j.jpeds.2008.06.011. Epub 2008 Jul 30. J Pediatr. 2008. PMID: 18672254 Free PMC article. Clinical Trial.
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, Oonishi T, Hashimoto K, Kobayashi N, Waki K, Suzuki Y, Otsubo Y, Yamada H, Ishikawa C, Kato T, Fuse S. Mori M, et al. Sci Rep. 2018 Jan 31;8(1):1994. doi: 10.1038/s41598-017-18387-7. Sci Rep. 2018. PMID: 29386515 Free PMC article. Clinical Trial.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback